EIS Eczacibasi Ilac, Sinai ve Finansal Yatirimlar Sanayi ve Ticaret A.S.
EIS Eczacibasi Ilaç, Sinai ve Finansal Yatirimlar Sanayi ve Ticaret A.S., together with subsidiaries, engages in health and real estate development businesses in Turkey and internationally. The Health segment is involved in the production, marketing, and sale of medicines related to human health and veterinary medicines. The Real Estate Development segment engages in development of real estate properties; rental activities for serum facilities; and providing consulting services on land development and project management. The company was incorporated in 1951 and is based in Istanbul, Turkey. EIS Eczacibasi Ilaç, Sinai ve Finansal Yatirimlar Sanayi ve Ticaret A.S. is a subsidiary of Eczacibasi Holding A.S.
Leadership team data not yet available for this company.
We're expanding our GCC coverage — check back soon.
2025 Interim Dividend Declaration - TRY 0.42 per Share
Sep 10, 2025
Acquisition of Specialty Pharmaceutical Distribution Assets
Jul 30, 2025
Notice of Extraordinary General Meeting - Capital Increase Proposal
Jun 15, 2025
Q1 2025 Financial Results - Strong Start to Year
May 20, 2025
Strategic Partnership Announced with International Pharmaceutical Distributor
May 8, 2025
2024 Corporate Sustainability and ESG Report Released
Apr 22, 2025
Regulatory Compliance Filing - Annual Corporate Governance Statement
Mar 20, 2025
EIS Eczacibasi 2024 Full Year Financial Results
Mar 15, 2025
2024 Final Dividend Payment Announcement - TRY 0.85 per Share
Mar 10, 2025
Notice of Annual General Meeting - April 2025
Mar 5, 2025
Metrics not yet available.
Poor
8-factor live score
SouqData provides data for informational purposes only. This does not constitute financial advice, a personal recommendation, or an offer to buy or sell any security. Information may contain errors or be outdated. Always verify data independently and consult a licensed financial adviser before making investment decisions.
Get unlimited access to 180+ insight pages, AI copilot, deep research reports, watchlists, portfolio tracking, and the full 210-column screener across 11 MENA exchanges.
